



MEN

**FIRST CANCER SITE
BREAST**
**BREAST
POOL AIRTUM 1976-2010, MEN:**

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

**MAMMELLA
POOL AIRTUM 1976-2010, UOMINI:**

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	1904		1982		1982		1904		1620		755		258		1904	1982
Person-years ▶	9402		9726		323		1458		4562		2391		991		9402	9726
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND BREAST	221	1.11	236	1.15	15	2.37	34	1.19	109	1.17	58	1.09	20	0.84	2.36	3.17
HEAD AND NECK	12	1.54	12	1.49	0	0.00	2	1.67	5	1.33	3	1.49	2	2.42	0.45	0.40
ORAL CAVITY	4	2.17	4	2.10	0	0.00	1	3.58	1	1.13	1	2.09	1	5.02	0.23	0.22
PHARYNX	3	1.84	3	1.78	0	0.00	1	4.01	1	1.26	1	2.38	0	0.00	0.15	0.13
LARYNX	5	1.15	5	1.12	0	0.00	0	0.00	3	1.43	1	0.90	1	2.20	0.07	0.05
OESOPHAGUS	3	1.45	3	1.40	0	0.00	0	0.00	2	2.03	1	1.85	0	0.00	0.10	0.09
STOMACH	15	1.22	15	1.18	0	0.00	1	0.54	11	1.88	3	0.93	0	0.00	0.29	0.24
COLON RECTUM	28	1.02	28	0.99	0	0.00	4	1.02	16	1.25	6	0.81	2	0.60	0.05	-0.04
COLON	24	1.27	24	1.23	0	0.00	4	1.50	13	1.48	5	0.97	2	0.85	0.54	0.46
RECTUM	4	0.47	4	0.45	0	0.00	0	0.00	3	0.74	1	0.44	0	0.00	-0.49	-0.50
LIVER	7	0.89	7	0.86	0	0.00	0	0.00	3	0.81	2	0.96	2	2.17	-0.09	-0.11
GALLBLADDER	3	1.38	3	1.33	0	0.00	0	0.00	1	0.98	1	1.73	1	3.87	0.09	0.08
PANCREAS	6	1.11	6	1.07	0	0.00	1	1.29	1	0.39	4	2.75	0	0.00	0.06	0.04
LUNG	33	0.96	43	1.21	10	8.92	5	0.99	15	0.93	8	0.88	5	1.27	-0.14	0.78
SKIN MELANOMA	2	0.73	2	0.71	0	0.00	0	0.00	0	0.00	1	1.35	1	2.90	-0.08	-0.08
MESOTHELIOMA	2	1.95	2	1.89	0	0.00	0	0.00	2	4.21	0	0.00	0	0.00	0.10	0.10
KAPOSI SARCOMA	1	2.36	1	2.29	0	0.00	0	0.00	1	4.94	0	0.00	0	0.00	0.06	0.06
SOFT TISSUE	1	1.47	1	1.42	0	0.00	0	0.00	0	0.00	1	5.51	0	0.00	0.03	0.03
BONE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
BREAST	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.05	-0.05
PROSTATE	51	1.30	52	1.29	1	0.84	10	1.85	23	1.27	15	1.40	3	0.60	1.25	1.19
TESTIS	1	4.75	2	9.17	1	132.44	0	0.00	0	0.00	1	19.32	0	0.00	0.08	0.18
KIDNEY AND RENAL PELVIS	14	2.31	15	2.40	1	5.29	5	5.81	5	1.76	2	1.23	2	2.74	0.84	0.90
BLADDER AND URINARY TRACT	23	1.04	23	1.00	0	0.00	2	0.62	15	1.44	5	0.84	1	0.38	0.09	0.01
URINARY BLADDER	22	1.04	22	1.00	0	0.00	2	0.65	15	1.51	4	0.71	1	0.40	0.08	0.01
URINARY TRACT	1	1.04	1	1.01	0	0.00	0	0.00	0	0.00	1	3.84	0	0.00	0.00	0.00
BRAIN AND CENTRAL NERVOUS SYSTEM	3	1.37	3	1.33	0	0.00	0	0.00	2	1.92	1	1.74	0	0.00	0.09	0.08
THYROID	2	2.37	2	2.29	0	0.00	2	16.21	0	0.00	0	0.00	0	0.00	0.12	0.12
HODGKIN LYMPHOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
NON-HODGKIN LYMPHOMA	3	0.54	4	0.70	1	5.71	1	1.26	2	0.77	0	0.00	0	0.00	-0.27	-0.18
MYELOMA	1	0.38	1	0.37	0	0.00	0	0.00	1	0.80	0	0.00	0	0.00	-0.17	-0.18
LEUKAEMIAS	2	0.44	2	0.42	0	0.00	0	0.00	0	0.00	2	1.65	0	0.00	-0.27	-0.28
LYMPHOID LEUKAEMIAS	1	0.46	1	0.44	0	0.00	0	0.00	0	0.00	1	1.75	0	0.00	-0.13	-0.13
MYELOID LEUKAEMIAS	1	0.49	1	0.47	0	0.00	0	0.00	0	0.00	1	1.81	0	0.00	-0.11	-0.12
OTHER LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
OTHER AND ILL DEFINED SITES	8	0.76	9	0.83	1	2.96	1	0.66	4	0.81	2	0.71	1	0.80	-0.27	-0.19

Decrease/Difetto
Increase/Eccesso

O Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio



WOMEN

FIRST CANCER SITE
BREAST

BREAST

POOL AIRTUM 1976-2010, WOMEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

MAMMELLA

POOL AIRTUM 1976-2010, DONNE:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months				
	No. of subjects alive at interval beginning ▶	Person-years ▶	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR				
SECOND CANCER SITE			O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR				
ALL SITES, BUT SKIN AND BREAST	10597	1274882	11137	1.12	222246	1.14	540	2.23	215809	1.00	193012	1.09	3092	1.15	1941	1.21	0.86	1.07		
HEAD AND NECK	178		187	1.04	222246	1.07	9	2.06	215809	0.78	193012	0.98	72	0.98	56	1.20	0.01	0.01		
ORAL CAVITY	99		101	1.10		1.10	2	0.89		0.66		1.10	42	1.10	32	1.25	0.01	0.01		
PHARYNX	42		45	1.06		1.11	3	2.84		0.81		0.91	16	0.91	13	1.17	0.00	0.00		
LARYNX	37		41	0.89		0.96	4	3.70		0.99		0.78	14	0.78	11	0.94	0.00	0.00		
OESOPHAGUS	81		88	1.34		1.42	7	4.59		1.12		1.13	29	1.13	20	1.17	24	2.30	0.02	0.02
STOMACH	758		775	1.08		1.08	17	0.92		0.81		1.10	333	1.10	215	1.09	140	1.22	0.04	0.04
COLON RECTUM	2124		2171	1.10		1.10	47	0.97		1.02		1.11	910	1.11	599	1.09	383	1.15	0.15	0.15
COLON	1511		1546	1.09		1.09	35	1.02		1.02		1.08	633	1.09	427	1.08	287	1.19	0.10	0.10
RECTUM	613		625	1.12		1.11	12	0.86		1.04		1.11	277	1.18	172	1.11	96	1.05	0.05	0.05
LIVER	271		279	0.85		0.85	8	1.00		0.98		0.84	113	0.84	71	0.78	50	0.89	-0.04	-0.04
GALLBLADDER	208		214	0.82		0.82	6	0.91		0.91		0.83	90	0.83	63	0.87	43	0.99	-0.04	-0.04
PANCREAS	515		526	1.05		1.05	11	0.93		0.79		0.97	197	0.97	175	1.24	99	1.11	0.02	0.02
LUNG	823		929	1.02		1.12	106	5.41		1.02		0.96	326	0.96	235	1.01	168	1.17	0.01	0.08
SKIN MELANOMA	309		346	1.21		1.32	37	5.56		0.83		1.33	148	1.33	85	1.18	50	1.24	0.04	0.06
MESOTHELIOMA	29		30	0.84		0.85	1	1.21		1.28		0.76	11	0.76	5	0.50	8	1.26	0.00	0.00
KAPOSI SARCOMA	8		9	0.50		0.55	1	2.45		0.53		0.30	2	0.30	3	0.66	2	0.71	-0.01	-0.01
SOFT TISSUE	83		83	1.53		1.49	0	0.00		0.91		1.41	33	1.41	26	1.70	18	2.02	0.02	0.02
BONE	15		15	1.03		1.00	0	0.00		0.54		0.94	6	0.94	4	0.99	4	1.77	0.00	0.00
BREAST	43		63	0.01		0.02	20	0.21		0.00		0.01	14	0.01	22	0.02	6	0.01	-2.74	-2.72
CERVIX UTERI	186		188	1.02		1.00	2	0.37		1.23		0.93	78	0.93	54	1.11	23	0.95	0.00	0.00
CORPUS UTERI	1222		1302	1.94		2.02	80	4.88		1.22		1.97	539	1.97	371	2.09	218	2.17	0.47	0.50
OVARY	596		615	1.42		1.43	19	1.70		1.22		1.27	234	1.27	171	1.46	127	1.93	0.14	0.14
KIDNEY AND RENAL PELVIS	442		497	1.43		1.57	55	7.22		3.29		1.13	148	1.13	114	1.28	62	1.15	0.10	0.14
BLADDER AND URINARY TRACT	520		534	1.11		1.11	14	1.21		1.03		1.07	210	1.07	164	1.22	90	1.09	0.04	0.04
URINARY BLADDER	496		509	1.14		1.14	13	1.20		1.05		1.11	203	1.11	156	1.25	84	1.10	0.05	0.05
URINARY TRACT	24		25	0.74		0.75	1	1.26		0.81		0.51	7	0.51	8	0.86	6	1.02	-0.01	-0.01
BRAIN AND CENTRAL NERVOUS SYSTEM	138		142	0.73		0.74	4	0.82		0.61		0.78	63	0.78	33	0.62	28	0.90	-0.04	-0.04
THYROID	376		401	1.37		1.42	25	3.39		1.21		1.38	168	1.38	119	1.55	47	1.15	0.08	0.09
HODGKIN LYMPHOMA	30		37	0.94		1.12	7	7.38		1.36		0.82	12	0.82	6	0.71	6	1.35	0.00	0.00
NON-HODGKIN LYMPHOMA	453		489	0.95		1.00	36	2.98		0.81		0.87	177	0.87	138	1.01	92	1.14	-0.02	0.00
MYELOMA	201		209	0.93		0.95	8	1.48		0.83		0.90	82	0.90	55	0.90	43	1.17	-0.01	-0.01
LEUKAEMIAS	377		384	1.25		1.24	7	0.90		0.82		1.39	180	1.39	113	1.32	54	1.07	0.06	0.06
LYMPHOID LEUKAEMIAS	132		138	1.00		1.01	6	1.73		0.80		1.12	64	1.12	41	1.10	14	0.64	0.00	0.00
MYELOID LEUKAEMIAS	223		224	1.53		1.50	1	0.27		0.81		1.75	109	1.75	66	1.60	34	1.37	0.06	0.06
OTHER LEUKAEMIAS	22		22	0.91		0.88	0	0.00		1.02		0.68	7	0.68	6	0.87	6	1.47	0.00	0.00
OTHER AND ILL DEFINED SITES	654		687	0.73		0.75	33	1.47		0.55		0.71	271	0.71	197	0.78	128	0.82	-0.19	-0.17

■ Decrease/Difetto ■ Increase/Eccesso ○ Observed cases / Casi osservati ■ SIR Standardized Incidence Ratio / Rapporto standardizzato di incidenza ■ EAR Excess Absolute Risk / Eccesso assoluto di rischio